Exenatide and Metformin Therapy in Overweight Women With PCOS

NCT00344851 on ClinicalTrials.gov · last registry update 2007-07-11

Finished, after enrolling 60 people. Primary outcome, as filed: - Menstrual Cyclicity ( # menses/ 24 weeks). exenatide is approved in the US, but not for pcos — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P2
Drug: exenatide
Bydureon, Byetta
Sponsor: Metabolic Center of Louisiana Research Foundation
Sponsor type: Other
Enrollment: 60
Started: 2006-06

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

- Menstrual Cyclicity ( # menses/ 24 weeks)

Conditions studied

Polycystic Ovary Syndrome

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.